CY1116133T1 - Κλασματα θρομβοσπονδινης (thrombospondin) και χρησεις αυτων σε κλινικες δοκιμες για καρκινο και δημιουργια αντισωματων και αλλων παραγοντων συνδεσης - Google Patents
Κλασματα θρομβοσπονδινης (thrombospondin) και χρησεις αυτων σε κλινικες δοκιμες για καρκινο και δημιουργια αντισωματων και αλλων παραγοντων συνδεσηςInfo
- Publication number
- CY1116133T1 CY1116133T1 CY20151100292T CY151100292T CY1116133T1 CY 1116133 T1 CY1116133 T1 CY 1116133T1 CY 20151100292 T CY20151100292 T CY 20151100292T CY 151100292 T CY151100292 T CY 151100292T CY 1116133 T1 CY1116133 T1 CY 1116133T1
- Authority
- CY
- Cyprus
- Prior art keywords
- thrombospondin
- cancer
- fractions
- clinical tests
- creating antibodies
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 102000002938 Thrombospondin Human genes 0.000 title abstract 2
- 108060008245 Thrombospondin Proteins 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 3
- 238000002405 diagnostic procedure Methods 0.000 abstract 2
- 210000001124 body fluid Anatomy 0.000 abstract 1
- 239000010839 body fluid Substances 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4728—Details alpha-Glycoproteins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/25375—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Η εφεύρεση σχετίζεται με κλάσματα θρομβοσπονδίνης (thrombospondin) που βρίσκονται στο πλάσμα, την χρήση τους ή την χρήση τμημάτων αυτών σε διαγνωστικές μεθόδους, όπως μεθόδους παραγόντων βαθμονόμησης, μεθόδους παραγόντων ένδειξης, και σαν ανοσογόνα, και σαν αναλυτές για μεθόδους με ουσιαστική κλινική χρησιμότητα, και την ανίχνευση τους στο πλάσμα ή άλλα σωματικά υγρά για τον σκοπό διαγνωστικών μεθόδων, ειδικότερα για καρκίνο.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40549402P | 2002-08-23 | 2002-08-23 | |
US10/419,462 US7655411B2 (en) | 2002-08-23 | 2003-04-21 | Thrombospondin fragments and binding agents in the detection, diagnosis and evaluation of cancer |
EP03793149.0A EP1572225B1 (en) | 2002-08-23 | 2003-08-20 | Thrombospondin fragments and uses thereof in clinical assays for cancer and generation of antibodies and other binding agents |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1116133T1 true CY1116133T1 (el) | 2017-02-08 |
Family
ID=31949896
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20151100292T CY1116133T1 (el) | 2002-08-23 | 2015-03-23 | Κλασματα θρομβοσπονδινης (thrombospondin) και χρησεις αυτων σε κλινικες δοκιμες για καρκινο και δημιουργια αντισωματων και αλλων παραγοντων συνδεσης |
Country Status (11)
Country | Link |
---|---|
US (8) | US7655411B2 (el) |
EP (1) | EP1572225B1 (el) |
AU (1) | AU2003262727A1 (el) |
CA (1) | CA2496984C (el) |
CY (1) | CY1116133T1 (el) |
DK (1) | DK1572225T3 (el) |
ES (1) | ES2533452T3 (el) |
IL (2) | IL166982A (el) |
PT (1) | PT1572225E (el) |
SI (1) | SI1572225T1 (el) |
WO (1) | WO2004018995A2 (el) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7655411B2 (en) | 2002-08-23 | 2010-02-02 | W2 Holdings, Inc. | Thrombospondin fragments and binding agents in the detection, diagnosis and evaluation of cancer |
CA2587463A1 (en) * | 2004-11-16 | 2006-11-30 | Avidia Research Institute | Protein scaffolds and uses therof |
GB0523828D0 (en) * | 2005-11-23 | 2006-01-04 | Ares Trading Sa | Thrombospondin domain-containing cell surface recognition molecules |
US7811549B2 (en) | 2006-07-05 | 2010-10-12 | Adenobio N.V. | Methods, compositions, unit dosage forms, and kits for pharmacologic stress testing with reduced side effects |
EP2695896B1 (en) | 2006-10-06 | 2018-08-22 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Prevention of tissue ischemia, related methods and compositions |
EP1930729A1 (en) * | 2006-12-04 | 2008-06-11 | Medizinische Universität Wien | Method for in vivo and in vitro testing for a pharmaceutical drug induced immediate type hypersensitivity reactions |
US20090185973A1 (en) * | 2008-01-22 | 2009-07-23 | Adenobio N.V. | Methods, compositions, unit dosage forms, and kits for pharmacologic stress testing with reduced side effects |
JP2012506538A (ja) * | 2008-10-21 | 2012-03-15 | アスチュート メディカル,インコーポレイテッド | 腎損傷および腎不全の診断および予後のための方法および組成物 |
CA2905418C (en) * | 2013-03-13 | 2023-03-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for modulating chemotherapeutic cytotoxicity |
CN104075931B (zh) * | 2013-03-29 | 2016-08-03 | 中国科学院大连化学物理研究所 | 一种蛋白质样品原位快速预处理方法 |
CN106885908B (zh) * | 2015-12-23 | 2019-05-07 | 中国人民解放军第二军医大学 | 血清psmd4蛋白的检测试剂盒及其检测方法与应用 |
CN105801694A (zh) * | 2016-05-03 | 2016-07-27 | 上海科新生物技术股份有限公司 | 一种抗心磷脂/β2糖蛋白I复合物的嵌合抗体 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4610960A (en) * | 1983-12-21 | 1986-09-09 | Wisconsin Alumni Research Foundation | Monoclonal antibody to thrombospondin and method for assaying for and isolating thrombospondin |
US4820505A (en) * | 1985-04-04 | 1989-04-11 | Scripps Clinic And Research Foundation | Detection of activated platelets with antibodies to thrombospondin |
US5192744A (en) * | 1990-01-12 | 1993-03-09 | Northwestern University | Method of inhibiting angiogenesis of tumors |
US6239110B1 (en) * | 1990-02-22 | 2001-05-29 | W.R. Grace & Co. -Conn. | Synthetic analogs of thrombospondin and therapeutic use thereof |
US5840692A (en) * | 1990-02-22 | 1998-11-24 | Allegheny University Of The Health Sciences | Peptide fragments and analogs of thrombospondin |
US5256538A (en) * | 1991-03-08 | 1993-10-26 | Board Of Regents, The University Of Texas System | Detection of early platelet activation and prediagnosis of thrombotic events |
CA2063055A1 (en) * | 1991-05-22 | 1992-11-23 | Jacob Eyal | Peptides having thrombospondin-like activity and their therapeutic use |
US5770563A (en) * | 1991-12-06 | 1998-06-23 | The United States Of America As Represented By The Department Of Health And Human Services | Heparin- and sulfatide binding peptides from the type I repeats of human thrombospondin and conjugates thereof |
DE4203545A1 (de) * | 1992-02-07 | 1993-08-12 | Behringwerke Ag | Spezifische antikoerper gegen aktivierte plaettchen, ihre herstellung und ihre verwendung in diagnose und therapie |
US5279966A (en) * | 1992-04-02 | 1994-01-18 | The Trustees Of Columbia University In The City Of New York | Cloning, expression and uses of a novel secreted protein, F-spondin |
US5753517A (en) * | 1996-03-29 | 1998-05-19 | University Of British Columbia | Quantitative immunochromatographic assays |
AU4298297A (en) * | 1996-08-15 | 1998-03-06 | Novartis Ag | Assay for quantifying arthritic conditions |
US5840507A (en) * | 1997-03-19 | 1998-11-24 | Oncotech, Inc. | Methods for cancer prognosis and diagnosis |
US5922551A (en) * | 1997-03-20 | 1999-07-13 | Accumetrics, Inc. | Agglutrimetric platelet binding assays in blood |
US6339062B1 (en) * | 1998-11-23 | 2002-01-15 | Inkine Pharmaceutical Company, Inc. | Retroinverso polypeptides that mimic or inhibit thrombospondin activity |
EA200100264A1 (ru) | 1999-06-21 | 2001-10-22 | Филадельфия Хеалс Энд Эдьюкейшн Корпорейшн | Ангиоцидин: адгезионный рецептор опухолей клетки, специфический для cys-ser-val-thr-cys-gly |
EP1254181B1 (en) * | 1999-08-30 | 2006-10-25 | WesaGen, Inc | Diagnostic assay for type 2 heparin-induced thrombocytopenia |
US6727063B1 (en) * | 1999-09-10 | 2004-04-27 | Millennium Pharmaceuticals, Inc. | Single nucleotide polymorphisms in genes |
US20010041670A1 (en) * | 1999-12-06 | 2001-11-15 | Ronit Simantov | Thrombospondin-binding region of histidine-rich glycoprotein and method of use |
US20030166017A1 (en) * | 2000-11-09 | 2003-09-04 | Millennium Pharmaceuticals, Inc. | Compositions and methods for the identification, assessment, prevention and therapy of cardiovascular disease |
US20030119074A1 (en) * | 2001-12-20 | 2003-06-26 | George Jackowski | Diagnosis and treatment of dementia utilizing thrombospondin |
US7655411B2 (en) | 2002-08-23 | 2010-02-02 | W2 Holdings, Inc. | Thrombospondin fragments and binding agents in the detection, diagnosis and evaluation of cancer |
-
2003
- 2003-04-21 US US10/419,462 patent/US7655411B2/en not_active Expired - Fee Related
- 2003-08-20 EP EP03793149.0A patent/EP1572225B1/en not_active Expired - Lifetime
- 2003-08-20 DK DK03793149.0T patent/DK1572225T3/en active
- 2003-08-20 WO PCT/US2003/026023 patent/WO2004018995A2/en not_active Application Discontinuation
- 2003-08-20 SI SI200332417T patent/SI1572225T1/sl unknown
- 2003-08-20 PT PT37931490T patent/PT1572225E/pt unknown
- 2003-08-20 CA CA2496984A patent/CA2496984C/en not_active Expired - Fee Related
- 2003-08-20 AU AU2003262727A patent/AU2003262727A1/en not_active Abandoned
- 2003-08-20 ES ES03793149.0T patent/ES2533452T3/es not_active Expired - Lifetime
- 2003-08-20 US US10/525,610 patent/US20060257947A1/en not_active Abandoned
-
2004
- 2004-02-20 US US10/782,968 patent/US8053196B2/en not_active Expired - Fee Related
-
2005
- 2005-02-17 IL IL166982A patent/IL166982A/en not_active IP Right Cessation
-
2009
- 2009-06-17 IL IL199414A patent/IL199414A/en not_active IP Right Cessation
- 2009-08-19 US US12/543,855 patent/US8415107B2/en not_active Expired - Fee Related
-
2010
- 2010-02-26 US US12/713,952 patent/US20110065206A1/en not_active Abandoned
-
2011
- 2011-11-04 US US13/289,886 patent/US20120271124A1/en not_active Abandoned
- 2011-11-07 US US13/290,296 patent/US20120276559A1/en not_active Abandoned
-
2013
- 2013-04-08 US US13/858,217 patent/US20140051098A1/en not_active Abandoned
-
2015
- 2015-03-23 CY CY20151100292T patent/CY1116133T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP1572225A2 (en) | 2005-09-14 |
DK1572225T3 (en) | 2015-03-30 |
CA2496984C (en) | 2014-12-09 |
US20050065324A1 (en) | 2005-03-24 |
SI1572225T1 (sl) | 2015-05-29 |
US20060257947A1 (en) | 2006-11-16 |
US20040053392A1 (en) | 2004-03-18 |
AU2003262727A1 (en) | 2004-03-11 |
PT1572225E (pt) | 2015-04-07 |
IL199414A0 (en) | 2011-07-31 |
US20110065206A1 (en) | 2011-03-17 |
US8415107B2 (en) | 2013-04-09 |
AU2003262727A8 (en) | 2004-03-11 |
IL199414A (en) | 2015-07-30 |
IL166982A (en) | 2014-09-30 |
CA2496984A1 (en) | 2004-03-04 |
WO2004018995A3 (en) | 2004-09-10 |
ES2533452T3 (es) | 2015-04-10 |
EP1572225B1 (en) | 2014-12-24 |
US20120276559A1 (en) | 2012-11-01 |
US20100155245A1 (en) | 2010-06-24 |
EP1572225A4 (en) | 2009-07-01 |
US8053196B2 (en) | 2011-11-08 |
US20120271124A1 (en) | 2012-10-25 |
US7655411B2 (en) | 2010-02-02 |
US20140051098A1 (en) | 2014-02-20 |
WO2004018995A2 (en) | 2004-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1116133T1 (el) | Κλασματα θρομβοσπονδινης (thrombospondin) και χρησεις αυτων σε κλινικες δοκιμες για καρκινο και δημιουργια αντισωματων και αλλων παραγοντων συνδεσης | |
CY1120423T1 (el) | Β7-η1 και pd-1 στη θεραπεια του καρκινωματος νεφρικων κυτταρων | |
CY1119722T1 (el) | Δημιουργια και περιγραφη πληρως ανθρωπινων θεραπευτικων αντισωματων λαμβανομενων μεσω hucal gold ειδικων για ανθρωπινό cd38 | |
CY1121872T1 (el) | Αξιολογηση, δοκιμασιες και θεραπεια των pkal-μεσολαβουμενων διαταραχων | |
CY1120434T1 (el) | Πρωτεϊνες προσδεσης il-1 | |
CY1121162T1 (el) | M-csf-ειδικο μονοκλωνικο αντισωμα και χρησεις αυτου | |
CY1120913T1 (el) | Μονοκλωνικα αντισωματα εναντι προγαστρινης και η χρηση τους | |
CY1123030T1 (el) | Υλικο και μεθοδοι για θεραπεια ή αποτροπη σχετικων me her-3 ασθενειων | |
CY1122155T1 (el) | Συζευγμενες ενωσεις που περιλαμβανουν αντισωματα τροποποιημενης κυστεϊνης | |
CY1118880T1 (el) | Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις | |
CY1120296T1 (el) | ΔΙΑΛΥΤΟΣ ΥΠΟΔΟΧΕΑΣ ΕΝΕΡΓΟΠΟΙΗΤΗ ΤΟΥ ΠΛΑΣΜΙΝΟΓΟΝΟΥ ΤΥΠΟΥ ΟΥΡΟΚΙΝΑΣΗΣ (suPAR) ΩΣ ΔΙΑΓΝΩΣΤΙΚΟΣ ΔΕΙΚΤΗΣ ΓΙΑ ΧΑΜΗΛΟΥ ΒΑΘΜΟΥ ΦΛΕΓΜΟΝΗ | |
CY1119799T1 (el) | Συνδυασμος αντισωματων anti-kir και αντισωματων anti-pd-1 για αγωγη καρκινου | |
CY1118549T1 (el) | Χρηση anti-vegf αντισωματος σε συνδυασμο με χημειοθεραπεια για τη θεραπευτικη αγωγη του καρκινου του μαστου | |
CY1108294T1 (el) | Πρωτεϊνες καρκινικων δεικτων και οι χρησεις τους | |
CY1111649T1 (el) | Αντισωμα εναντι της γλυπικανης 3 | |
BRPI0618713B8 (pt) | cardiolipina modificada e seus usos | |
CY1112553T1 (el) | Ανοσοπροσδιορισμοι υψηλης ευαισθησιας και κιτια για τον προσδιορισμο πεπτιδιων και πρωτεϊνων βιολογικου ενδιαφεροντος | |
ES2570632T3 (es) | Procedimiento de determinación del inhibidor de elastasa de leucocito in vitro del cáncer colorrectal | |
HK1115636A1 (en) | Use of cyfra 21-1 as a marker for colorectal cancer cyfra 21-1 | |
ATE424560T1 (de) | Marker für neuromyelitis optica | |
CY1115212T1 (el) | Διαμεσολαβηση στην κυτταροτοξικοτητα των κυτταρων που παρουσιαζουν eπιφaneiakh εκφραση της cd44 | |
CR10143A (es) | Antígenos de ácido des-n-acetil-siálico, anticuerpos para los mismos y métodos de uso en la terapia del cáncer | |
DK2021794T3 (da) | Anvendelse af protein S100A 12 som en markør for colorektal cancer | |
BR0317394A (pt) | Uso de nicotinamida n-metiltransferase como um marcador para câncer colorretal | |
DE602005013430D1 (de) | Verwendung von asc als marker für kolorektalkarzinome |